How should I manage this patient’s diabetes regimen, including tirzepatide (Mounjaro) 2.5 mg weekly, insulin glargine (Lantus) 20 units every 12 hours, and rapid‑acting insulin 5 units before each meal, given an HbA1c of 13.2 %, C‑peptide of 8.2 ng/mL, and current fluconazole therapy for urinary yeast infection?

Diabetes Management Optimization with Aggressive Insulin Dose Reduction

You must immediately reduce both basal and bolus insulin doses by at least 25-30% while continuing tirzepatide, as this patient is severely over-insulinized with a markedly elevated C-peptide of 8.2 ng/mL indicating substantial endogenous insulin production, creating high risk for hypoglycemia and weight gain that counteracts tirzepatide's benefits.

Critical Assessment of Current Regimen

This patient's regimen is fundamentally problematic:

• Excessive basal insulin: Lantus 20 units every 12 hours (40 units/day total) is inappropriately high
• Unnecessary prandial insulin: 5 units TID (15 units/day) adds to over-insulinization
• Subtherapeutic tirzepatide: 2.5 mg weekly is the starting dose, not a maintenance dose
• C-peptide 8.2 ng/mL: This is 2-4 times normal fasting levels (1.1-4.4 ng/mL), indicating robust pancreatic beta-cell function and insulin resistance, not insulin deficiency

The HbA1c of 13.2% reflects inadequate glycemic control despite massive insulin doses, not because of insufficient insulin.

Immediate Insulin Adjustment Protocol

Step 1: Reduce Basal Insulin Immediately

Reduce Lantus from 40 units/day to 20-24 units once daily 1:

• Consolidate to once-daily dosing (Lantus is approved for once-daily administration)
• Start with 20 units once daily at bedtime
• This represents a 50% total daily basal dose reduction

Rationale: Research demonstrates that tirzepatide reduces total daily insulin requirements by approximately 25-30% within 2 months, with basal insulin showing the most dramatic reduction 2. In the SURPASS-5 trial, patients on tirzepatide required mean basal insulin doses of 29-38 units/day at 40 weeks, compared to 59 units/day with placebo 3.

Step 2: Eliminate or Drastically Reduce Prandial Insulin

Discontinue the 5 units TID prandial insulin immediately, or if you prefer a more conservative approach, reduce to 2-3 units before the largest meal only.

Rationale:

• Tirzepatide provides substantial postprandial glucose control through GLP-1 receptor agonism 4, 5
• The patient's elevated C-peptide indicates preserved beta-cell function that will respond to tirzepatide's incretin effects
• In SURPASS-5, patients successfully achieved glycemic targets with tirzepatide plus basal insulin alone, without prandial insulin 3
• Research shows bolus insulin requirements decrease significantly (from median 31.4 to 17.9 units/day) within 2 months of tirzepatide initiation 2

Step 3: Escalate Tirzepatide Aggressively

Increase tirzepatide from 2.5 mg to 5 mg weekly immediately, then:

• Advance to 10 mg weekly after 4 weeks
• Advance to 15 mg weekly after another 4 weeks if HbA1c remains >7%

Rationale: The 2.5 mg dose is only a starting dose for tolerability 3. In SURPASS trials, the 10 mg and 15 mg doses achieved HbA1c reductions of 2.0-2.4% from baseline, with mean baseline HbA1c of 8.1-8.6% 3, 6. This patient's HbA1c of 13.2% requires maximal tirzepatide dosing.

Monitoring and Titration Algorithm

Weeks 1-2 After Insulin Reduction:

• Check fasting glucose daily
• Check pre-meal and 2-hour postprandial glucose at least twice daily
• Target fasting glucose: 100-130 mg/dL (not <100 mg/dL given the insulin reduction)
• If fasting glucose consistently >180 mg/dL, increase bedtime Lantus by 2 units every 3 days 7
• If fasting glucose <70 mg/dL, decrease Lantus by 10-20% 7

Weeks 2-4:

• Continue glucose monitoring
• Assess for hypoglycemia (the elevated C-peptide plus tirzepatide plus insulin creates risk)
• If postprandial glucose consistently >250 mg/dL, consider adding back 2-4 units rapid-acting insulin before the largest meal 7

Month 2 and Beyond:

• Recheck HbA1c at 3 months
• Expected HbA1c reduction: 2-2.5% with optimized tirzepatide dosing 6
• Continue tirzepatide dose escalation to 15 mg if HbA1c >7%
• Further reduce or eliminate basal insulin if HbA1c approaches target with hypoglycemia risk

Critical Pitfalls to Avoid

Do not maintain current insulin doses "to be safe": This patient is already experiencing treatment failure at 40 units basal + 15 units bolus daily. The elevated C-peptide proves they don't have insulin deficiency. Continuing high insulin doses will:

• Cause weight gain (counteracting tirzepatide's weight loss benefit)
• Increase hypoglycemia risk as tirzepatide takes effect
• Perpetuate insulin resistance
• Lead to continued poor glycemic control

Do not titrate tirzepatide slowly: The 2.5 mg dose is inadequate for this degree of hyperglycemia. The evidence shows 10-15 mg doses are needed for optimal HbA1c reduction 3, 5, 6.

Do not ignore the C-peptide result: A C-peptide of 8.2 ng/mL indicates this patient has type 2 diabetes with significant insulin resistance and preserved beta-cell function, not type 1 diabetes or advanced beta-cell failure. They will respond robustly to tirzepatide's incretin effects.

Fluconazole Consideration

The fluconazole for urinary yeast is appropriate and should be completed as prescribed. For fluconazole-susceptible organisms, oral fluconazole 200 mg daily for 2 weeks is the standard recommendation 8. This will not significantly impact diabetes management, though monitor for potential drug interactions if the patient is on sulfonylureas (which they should not be given the insulin regimen).

Expected Outcomes

With this aggressive insulin reduction and tirzepatide escalation strategy:

• HbA1c reduction: Expect 2-2.5% reduction over 3-6 months (from 13.2% to approximately 10.5-11%)
• Weight loss: Expect 6-12 kg weight loss over 6 months 3, 6
• Insulin requirements: Total daily insulin should decrease to 20-30 units/day or less 2
• Hypoglycemia risk: Low if insulin is appropriately reduced 4, 5

The key to success is aggressive insulin dose reduction concurrent with tirzepatide escalation, not timid adjustments that perpetuate treatment failure.